Spark Therapeutics Inc (ONCE) Expected to Post Quarterly Sales of $53.75 Million

Brokerages expect that Spark Therapeutics Inc (NASDAQ:ONCE) will report $53.75 million in sales for the current quarter, Zacks Investment Research reports. Eight analysts have provided estimates for Spark Therapeutics’ earnings, with the lowest sales estimate coming in at $3.00 million and the highest estimate coming in at $119.00 million. Spark Therapeutics reported sales of $1.27 million during the same quarter last year, which would indicate a positive year over year growth rate of 4,132.3%. The business is expected to announce its next earnings report on Tuesday, May 8th.

According to Zacks, analysts expect that Spark Therapeutics will report full-year sales of $53.75 million for the current year, with estimates ranging from $80.00 million to $239.52 million. For the next financial year, analysts anticipate that the firm will report sales of $152.05 million per share, with estimates ranging from $76.99 million to $229.40 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Spark Therapeutics.

How to Become a New Pot Stock Millionaire

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Tuesday, February 20th. The biotechnology company reported ($1.73) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($1.73). The firm had revenue of $7.41 million during the quarter, compared to analyst estimates of $9.53 million. Spark Therapeutics had a negative net margin of 2,100.80% and a negative return on equity of 59.38%.

A number of equities research analysts have recently weighed in on ONCE shares. SunTrust Banks boosted their price objective on shares of Spark Therapeutics to $113.00 and gave the stock a “buy” rating in a report on Thursday, January 4th. ValuEngine lowered shares of Spark Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Credit Suisse Group initiated coverage on shares of Spark Therapeutics in a report on Wednesday, January 17th. They issued an “outperform” rating and a $61.00 price objective for the company. Cantor Fitzgerald set a $105.00 price target on shares of Spark Therapeutics and gave the company a “buy” rating in a report on Tuesday, December 19th. Finally, Barclays reiterated a “buy” rating and set a $64.00 price target (up from $61.00) on shares of Spark Therapeutics in a report on Tuesday, January 23rd. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and sixteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $70.58.

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in shares of Spark Therapeutics by 1.4% in the 4th quarter. BlackRock Inc. now owns 2,650,258 shares of the biotechnology company’s stock worth $136,277,000 after buying an additional 35,801 shares during the period. JPMorgan Chase & Co. grew its position in Spark Therapeutics by 15.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock valued at $164,986,000 after purchasing an additional 241,016 shares during the last quarter. Janus Henderson Group PLC grew its position in Spark Therapeutics by 46.4% during the 3rd quarter. Janus Henderson Group PLC now owns 756,088 shares of the biotechnology company’s stock valued at $67,413,000 after purchasing an additional 239,723 shares during the last quarter. Clearbridge Investments LLC grew its position in Spark Therapeutics by 2.9% during the 4th quarter. Clearbridge Investments LLC now owns 687,444 shares of the biotechnology company’s stock valued at $35,348,000 after purchasing an additional 19,492 shares during the last quarter. Finally, Rock Springs Capital Management LP grew its position in Spark Therapeutics by 3.0% during the 4th quarter. Rock Springs Capital Management LP now owns 615,000 shares of the biotechnology company’s stock valued at $31,623,000 after purchasing an additional 18,000 shares during the last quarter. 99.87% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Spark Therapeutics (NASDAQ:ONCE) opened at $61.58 on Friday. The firm has a market cap of $2,334.28, a P/E ratio of -7.97 and a beta of 2.82. Spark Therapeutics has a 1-year low of $41.06 and a 1-year high of $91.75.

COPYRIGHT VIOLATION WARNING: “Spark Therapeutics Inc (ONCE) Expected to Post Quarterly Sales of $53.75 Million” was first posted by Enterprise Leader and is the sole property of of Enterprise Leader. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://theenterpriseleader.com/2018/04/02/spark-therapeutics-inc-once-expected-to-post-quarterly-sales-of-53-75-million.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply